Key Highlights
- Elucid relocates to 399 Boylston Street, Boston.
- Move supports commercialization of flagship plaque analysis software.
- New office fosters collaboration and employee wellness.
- Follows $80M Series C fundraise led by Elevage Medical Technologies.
Source: Business Wire
Notable Quote
- “This new environment will foster stronger team connections and enhance our collaborative efforts, bringing our hybrid workforce together more effectively to develop and deliver meaningful products that improve patient care.” — Amy Kruglak, Vice President of People at Elucid
SoHC's Take
Elucid’s strategic move to Boston’s Back Bay positions the company advantageously for its next phase of growth. The modern, well-equipped headquarters will not only support the development and commercialization of its groundbreaking PlaqueIQ software but also provide an environment conducive to collaboration and employee well-being. With the backing of an $80 million Series C fundraise, Elucid is well-poised to advance its mission of improving patient care through innovative cardiovascular imaging solutions. This relocation is a significant step in Elucid’s three-year strategic plan, reinforcing its commitment to tackling the global challenge of cardiovascular disease with cutting-edge technology.
